​

Does Depo Provera Cause Pseudotumor Cerebri? A Pharmacovigilance Review

Legacy Context and Pharmacovigilance Evolution

The legacy domain has long served as a hub for general health and science information, bridging clinical care, public health, and technology to support informed decision-making. Within this broad context, discussions of pharmaceutical safety and adverse event surveillance have always been central, reflecting a commitment to understanding how medical interventions affect patient outcomes across diverse populations. This foundational perspective naturally extends to examining specific exposure scenarios where drug safety profiles intersect with rare but serious conditions. One such area of growing interest involves the relationship between hormonal contraceptive use and neurological adverse events. Specifically, the question of whether Depo Provera exposure may be associated with an elevated risk of Pseudotumor Cerebri represents a focused inquiry within the larger landscape of pharmacovigilance. This pivot from general health information to a targeted occupational exposure concern mirrors the domain’s evolution toward addressing nuanced, real-world clinical questions. By maintaining a neutral, evidence-informed stance, the transition allows for a rigorous exploration of causation without premature mechanistic claims, ensuring that the discussion remains grounded in the principles of public health and patient safety that have always defined the platform’s mission.

Pharmacological Mechanisms and Plausible Links

Depo Provera (medroxyprogesterone acetate) is a progestin-only injectable contraceptive used for long-term pregnancy prevention. Pseudotumor cerebri (idiopathic intracranial hypertension) is a condition characterized by elevated intracranial pressure without an identifiable mass lesion, presenting with headache, papilledema, and visual disturbances. The question of whether Depo Provera causes pseudotumor cerebri requires examination of pharmacological mechanisms, reported adverse events, and temporal relationships. Depo Provera's mechanism involves suppression of gonadotropin secretion, leading to anovulation and endometrial thinning. Progestins can influence fluid balance and vascular permeability, potentially affecting cerebrospinal fluid dynamics. Pseudotumor cerebri has been associated with hormonal fluctuations, including those from oral contraceptives and hormonal therapies. The progestin component may alter venous sinus pressure or cerebrospinal fluid absorption, though specific mechanistic pathways linking Depo Provera to pseudotumor cerebri are not fully established in the available evidence.

​

Evidence from Post-Marketing Surveillance and Labeling

The FDA Adverse Event Reporting System (FAERS) database provides post-marketing surveillance data. For Lamictal (lamotrigine), a drug with a different indication, FAERS reports include headache (3408 reports) and other neurological symptoms (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:LAMICTAL). While this does not directly address Depo Provera, it illustrates the utility of FAERS in identifying adverse events. For Depo Provera, FAERS data would be expected to capture reports of pseudotumor cerebri if they occur, but the provided evidence does not include specific Depo Provera FAERS data. The FDA label for Bavencio (avelumab) includes warnings about embryo-fetal toxicity and cardiovascular events (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118). This highlights the importance of labeling for serious adverse effects. For Depo Provera, the label includes warnings about bone mineral density loss and thromboembolic disorders, but pseudotumor cerebri is not listed as a specific warning in the provided evidence. The Lamictal label discusses risk factors for severe rash, including coadministration with valproate and exceeding recommended doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678). This demonstrates how labeling can identify risk factors and timing of adverse events. For pseudotumor cerebri, potential risk factors include obesity, female sex, and reproductive age, which overlap with Depo Provera users. The timeline for pseudotumor cerebri onset after Depo Provera initiation is not specified in the provided evidence, but case reports suggest it may occur within weeks to months of exposure. The Lamictal label also notes that estrogen-containing oral contraceptives can decrease serum concentrations of lamotrigine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678). This interaction highlights hormonal influences on drug metabolism. For Depo Provera, the progestin may similarly affect other medications, but direct evidence linking it to pseudotumor cerebri is lacking. A PubMed analysis of metoclopramide and prucalopride FAERS data shows that post-marketing reports can identify adverse drug reactions such as tardive dyskinesia and dystonia (https://pubmed.ncbi.nlm.nih.gov/38995209/). This underscores the value of FAERS in detecting rare events. For Depo Provera, pseudotumor cerebri would be a rare event, and FAERS data could help establish a signal, though the provided evidence does not include such data.

Causation Considerations and Clinical Implications

Regarding causation considerations, affected patients may need to demonstrate a temporal relationship between Depo Provera use and pseudotumor cerebri onset, as well as exclusion of other causes. The adequacy of warnings is a concern: if pseudotumor cerebri is not listed in the label, patients and clinicians may not be aware of the potential risk. The timeline between exposure and harm is critical; if pseudotumor cerebri develops shortly after Depo Provera initiation, it strengthens the association. In summary, while there is a plausible mechanistic link between progestins and pseudotumor cerebri, the provided evidence does not directly confirm that Depo Provera causes this condition. FAERS data for other drugs demonstrate the utility of post-marketing surveillance, but specific Depo Provera data are absent. The adequacy of warnings is questionable, and patients should be monitored for symptoms of pseudotumor cerebri, such as headache and visual changes, especially in the first months of use. Further research and pharmacovigilance are needed to clarify this potential association.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Protect your rights. Start your claim process here.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Submit for Legal Evaluation

Frequently Asked Questions

What is the evidence that Depo Provera causes pseudotumor cerebri?

The evidence is currently limited. While there is a plausible mechanistic link between progestins and pseudotumor cerebri, direct evidence from clinical trials or post-marketing surveillance specifically for Depo Provera is lacking. FAERS data for other drugs (e.g., Lamictal) demonstrate the utility of such databases, but no specific Depo Provera FAERS data are provided. The FDA label for Depo Provera does not list pseudotumor cerebri as a warning. Further research is needed.

What are the risk factors for pseudotumor cerebri in Depo Provera users?

Risk factors for pseudotumor cerebri include obesity, female sex, and reproductive age, which overlap with typical Depo Provera users. The timeline for onset after Depo Provera initiation is not well-defined, but case reports suggest it may occur within weeks to months. Patients should be monitored for symptoms such as headache and visual changes, especially early in treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Depo Provera exposure linked to Pseudotumor Cerebri mechanisms and evidence
• Long term outcome of Pseudotumor Cerebri after Depo Provera exposure
• Recovery and management of Pseudotumor Cerebri linked to Depo Provera

References

1. FAERS Lamictal Data
2. Bavencio FDA Label
3. Lamictal FDA Label
4. PubMed FAERS Analysis

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.